rF1V-1018
DV2-DC02-02
Phase 2 mab active
Quick answer
rF1V-1018 for Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis is a Phase 2 program (mab) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
- Phase
- Phase 2
- Modality
- mab
- Status
- active